FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to immunology. What is presented is an antibody specifically binding to an epitope on CD43 and CEA and modified in a heavy and/or light chain constant region. There are disclosed polynucleotides, vector, host cell and methods for producing the antibody according to the invention, as well as pharmaceutical composition, kit and method of treating non-haemopoietic cancer.
EFFECT: this invention can find further application in therapy and diagnosing of CD43 or CEA mediated diseases.
35 cl, 15 tbl, 5 ex, 4 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES RECOGNISING CARBOHYDRATE CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS, AND METHODS OF USING SUCH | 2007 |
|
RU2461572C2 |
| ANTIBODIES RECOGNIZING CARBOHYDRATE-CONTAINING EPITOPE ON CD-43 AND CEA EXPRESSED ON CANCER CELLS AND METHODS OF APPLICATION | 2012 |
|
RU2616868C2 |
| CD43 ANTIBODIES AND USE THEREOF FOR TREATING CANCER | 2016 |
|
RU2694903C1 |
| TETRAVALENT ANTIBODIES TO PSGL-1 AND THEIR APPLICATIONS | 2017 |
|
RU2766000C2 |
| ANTI-PD-1 ANTIBODIES | 2017 |
|
RU2752832C2 |
| COVALENT DIANTIBODIES AND USE THEREOF | 2009 |
|
RU2593720C2 |
| METHOD OF TREATING EYE DISEASES | 2008 |
|
RU2434639C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2016 |
|
RU2650767C2 |
| INTERLEUKIN-13-BINDING PROTEINS | 2012 |
|
RU2605327C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
